Upon inoculation into neonatal rats, murine leukemia virus (MuLV) NT40 causes a non-in¯ammatory degeneration of the central nervous system. While microglia cells appear to be the major target cells within the brain parenchyma for neurovirulent MuLV, degenerating neurons do not express retroviral gene products. In order to protect rats from neuronal damage we treated retrovirally infected rats once with monoamine oxidase (MAO) B inhibitor Selegiline which ± under different conditions ± exerts neuroprotective effects. Unexpectedly, when administered at 17 days post-infection (d.p.i.) a single intraperitoneal dose of Selegilin (1 mg/kg bodyweight) signi®cantly shortened the incubation period for neurological disease. In contrast, Selegiline given in a lower dosage (0.05 mg/kg bodyweight) and/or at a different time point (13 d.p.i.) at the low (0.05 mg/kg bodyweight) and the high dose (1.0 mg/kg bodyweight) had no effect on the outcome of neurological disease. Animals treated with Selegiline (1.0 mg/kg bodyweight at 17 d.p.i.) contained higher amounts of viral loads in the CNS, higher numbers of brain cells expressing major histocompatibility complex class II molecules, and exhibited inhibition of MAO-B in comparison to untreated yet infected (control) animals. Supposedly, Selegiline activated the major target cell population of the CNS for MuLV-NT40, microglia, with the consequence of enhanced susceptibility for retroviral infection and triggered endogenous mechanism(s) involved in the pathogenesis of retroviral neurodegeneration.
Introduction
Infections with neurovirulent retroviruses can result in neurodegenerative disease. In rodents, some of the murine leukemia viruses (MuLV) cause a nonin¯ammatory neurodegeneration, restricted to selective areas of the central nervous system (CNS) and the spinal cord (Baszler and Zachary, 1990; Czub et al, 1994 Czub et al, , 1995 Kay et al, 1991) . Most neurovirulent MuLV as well as certain lentiviruses including the human, simian, and feline immunode®ciency viruses (HIV, SIV, FIV) exhibit a strong af®nity for cells of the monocytic lineage, i.e. in the CNS these viruses infect primarily microglia cells (Brinkmann et al, 1992; Czub et al, 1995 Czub et al, , 1996 Lynch et al, 1991) . However, while infected microglia cells appear not to be morphologically altered, degenerating neurons do not express retroviral gene products (Baszler and Zachary, 1990; Czub et al, 1994 Czub et al, , 1995 Kay et al, 1991; Koenig et al, 1986; Lynch et al, 1991; Wiley et al, 1986) . It is thus likely that neurons are damaged by indirect mechanism(s) probably initiated from retrovirally infected microglia cells.
Attempts to prevent retroviral neurodegeneration after establishing viral infections of the CNS have generally failed. In a previous study, for example, we demonstrated that an otherwise highly ef®cient antiviral immune response to MuLV-FB29 was incapable of clearing a retroviral infection from the brain . As immunological mechanisms appear to be ineffective on retroviral CNS infection, the goal of the current study was to prevent retroviral induced neurodegeneration by pharmacological treatment. We chose Selegiline, a drug that is used alone or in combination with levodopa for symptomatic treatment of Parkinson's disease (Myllyla È et al, 1996) . Selegiline is an irreversible inhibitor of monoamine oxidase (MAO) B and ± at higher concentrations ± inhibits the reuptake of dopamine in dopaminergic neurons (Gerlach et al, 1996) . Apart from its effects on MAO, Selegiline exerts some`trophic-like' activities on brain cells. While the molecular mechanisms responsible for these activities of Selegiline are not clear, they appear to protect neurons from neurodegenerative insults, both in vivo (Sano et al, 1997; Semkova et al, 1996; ThyagaRajan et al, 1998) and in vitro (Heikkila et al, 1984; Langston et al, 1984; Salonen et al, 1996; Zhang and Yu, 1995) . Here, we show that treatment of retrovirally infected rats with Selegiline accelerated retrovirally induced neurological disease, and enhanced retroviral gene expression within the CNS as well as microglial activation. We propose that otherwise bene®cial effects of Selegiline might be deleterious if retroviral infection of the CNS precedes treatment with Selegiline.
Results
Early onset of neurological disease of retrovirally infected rats after a single dose of Selegiline Intraperitoneal (ip) inoculation of neonatal rats with MuLV-NT40 caused neurological disease in almost all animals within 50 days. The incubation period was 38.3+1.4 days (mean+standard error of the mean (s.e.m.) (Figure 1 ). First clinical signs were re¯ex abnormalities of the hind-and forelimbs, followed by ataxia and ± in some advanced cases ± priapism .
In order to achieve prevention or retardation of neurological disease, we treated neonatally infected rats once with MAO-B inhibitor Selegiline (1.0 mg/ kg bodyweight) at 13 d.p.i., i.e. before spongiform vacuolization occurred in the brain which began around 16 d.p.i. When given at 13 d.p.i., Selegiline did neither change the overall incidence, nor the quality, nor the length of the incubation period (37.6+1.8 days) for retroviral induced neurological disease as compared to untreated NT40 infected rats (Figure 1) . Thus, neuroprotection appeared not to be achieved by Selegiline under these conditions. However, when Selegiline (1.0 mg/kg bodyweight) was administered ip into neonatally infected rats at 17 d.p.i., i.e. when pathological CNS alterations had already started to occur, the incubation period for neurological disease (33.7+1.8 days) was shortened by 5 ± 7 days in comparison to untreated infected rats (P50.05; Figure 1 ). In contrast, the length of the incubation period for neurological disease was not in¯uenced by lower doses of Selegiline given either at 13 or at 17 d.p.i. (0.05 mg/kg bodyweight, Figure 1 ; or 0.01 mg/kg bodyweight, data not shown).
Inhibition of MAO-B by Selegiline
One of the best characterized effects of Selegiline is the irreversible inhibition of MAO-B (Gerlach et al, 1996) . As acceleration of neurological disease was only observed when Selegiline was given in a dosage of 1.0 mg/kg bodyweight at 17 d.p.i. but not upon lower doses and/or administration at 13 d.p.i., we determined whether Selegiline induced acceleration of neurological disease correlated with inhibition of MAO-B. Lower doses of Selegiline did not inhibit MAO-B, neither when given at early or at later timepoints (at 17 d.p.i.) (Figure 2 ). Higher doses of Selegiline (1.0 mg/kg bodyweight) inhibited MAO-B by at least 60%, both, when given at 17 d.p.i. and at 13 d.p.i. (Figure  2 ). Thus, inhibition of MAO-B did not correlate with accelerated neurological disease.
Enhanced expression of MHC II within the CNS Activation of glia cells is supposed to play a dual role in the pathogenesis of retroviral induced disease. On the one hand, activated glia cells may shed neurotoxic substances like cytokines and may thus contribute to neurodegeneration (Masliah et al, 1996) . On the other hand, activation of glia cells has been demonstrated to result in enhanced suscept- Figure 1 In¯uence of Selegiline on MuLV-NT40 induced neurological disease. Fischer rats were infected intraperitoneally with murine retrovirus NT40 at birth and treated with Selegiline (1.0 and 0.05 mg/kg bodyweight, respectively) at 13 and 17 days postinfection, respectively, or left untreated. For each scheme of treatment, 3 ± 17 independent experiments were set up. Animals were scored positive for neurological disease when they repeatedly exhibited re¯ex abnormalities and/or other neurological signs. Mean incubation periods are depicted as symbols between bars (+s.e.m.). ibility for retroviral infection (Lynch et al, 1995) . Selegiline has been shown to induce expression of several cellular genes some of which are associated with activation of glia cells (Biagini et al, 1993) . Therefore, we determined numbers of activated cells within the brain, i.e. cells expressing MHC II. MHC II are only rarely found on glia cells from uninfected and/or untreated Fisher rats Lassmann et al, 1991) . In brain of NT40 infected yet untreated animals we found 81+36 cells expressing MHC II (mean+s.e.m.; n=15), whereas brains from infected Selegiline treated rats (1.0 mg/kg bodyweight at 17 d.p.i.) contained 219+51 (mean+s.e.m.; n=13) cells positive for MHC II immunolabeling (Table 1 ). These data show that retroviral infection in combination with Selegiline treatment triggered mechanism(s) resulting in enhanced activation of cells within the brain.
Selegiline enhanced expression of retroviral gene products in the CNS Previous work revealed that the length of the incubation period for retroviral induced neurological disease correlated with viral loads in the CNS, i.e. high amounts of virus within the CNS corresponded with short incubation periods and vice versa (Czub et al, 1992) . Employing an accurate technique, we determined the numbers of infected cells in the cerebellar cortex (CC) and in subcerebellar brainstem areas (SCBS) by means of immunohistochemistry at 25 ± 36 d.p.i. During the course of viral infection, these regions contain high numbers of infected cells, both endothelial cells of the blood vessels and microglia cells. However, only the subcerebellar regions are subjected to intensive spongiform vacuolization . In brains of NT40 infected yet untreated animals we found 308+75 cells expressing NT40 proteins (sum of CC: 112+35 and SCBS: 196+72; mean+s.e.m.; n=11), whereas brains of Selegiline treated rats (1.0 mg/kg bodyweight at 17 d.p.i.) contained 600+64 (sum of CC: 216+25 and SCBS: 384+48; mean+s.e.m.; n=12) cells positive for staining with antiviral immune serum (Table 1) . Similar results were obtained by in situ hybridizations (Figure 3) . Thus, based on immunohistochemical data, treatment with MAO-B inhibitor Selegiline (1.0 mg/kg bodyweight at 17 d.p.i.) enhanced the numbers of retrovirally infected cells within the brain by approximately twofold.
Additionally, we isolated mRNA from total brains at 25 ± 33 d.p.i. and quanti®ed the relative amounts of viral RNA, both full length and spliced. The mean signal strength of all viral transcripts from individual brains of untreated rats was 117+26 (mean+ 
Discussion
The major ®nding of our study is that in a rodent model for non-in¯ammatory neurodegeneration Selegiline ± under selective conditions ± enhanced progression of neurological disease. Our results contrast numerous reports on bene®cial effects of Selegiline, including those demonstrating treatment of Alzheimer's disease (Sano et al, 1997) and of Morbus Parkinson (Myllyla È et al, 1996) . It should be borne in mind, however, that the current study was performed with rats and not with primates including humans. It is also noteworth, that the dose of Selegiline used in our experiments was higher than the dose given to humans with Parkinson's disease. A key factor in the pathogenesis of retroviral induced neurodegeneration including the AIDSdementia complex is the level of retroviral load in the CNS. Previous work shows that high amounts of retroviral gene products in the CNS correlate with short incubation periods and a high incidence for neurological disease (Czub et al, 1992; Robertson et al, 1997) . The amount of viral load within the CNS and the cerebrospinal¯uid appears to be similarly important for the development of neurological disease upon infection with the human immunode®ciency virus (HIV) (McArthur et al, 1997; Robertson et al, 1998) . As animals treated with Selegiline (1.0 mg/kg bodyweight at 17 d.p.i.) contained higher amounts of viral loads in the CNS than those without Selegiline treatment, acceleration of neurological disease upon treatment with Selegiline is attributed to the enhanced levels of viral load within the CNS.
Enhanced progression of neurological disease induced by Selegiline (1.0 mg/kg bodyweight at 17 d.p.i.) not only correlated with high levels of Northern blots using mRNA from total rat brains. Blots were probed with a probe encoding retroviral envelopesequences which resulted in signals representing viral full length genomic (8,1 kb) and spliced transcripts (3,8 kb). Simultaneously, a probe encoding housekeeping gene GAPDH was used, hybridizing with transcripts of 1,2 kb. Virus speci®c hybridization signals were adjusted to comparable levels by dividing the signal strengths of the viral signals by the respective signal strengths of the GAPDH signals.
32 P-hybridization signals were analyzed and background corrected using a Phosphor imaging system from Molecular Dynamics. The mean signal strength of all viral transcripts from nine individual brains of untreated rats was 117+26 (mean+s.e.m.), while the mean signal strength of viral transcripts from nine brains of NT40 infected rats that were treated with Selegiline (1.0 mg/kg bodyweight at 17 d.p.i.) was 174+32 (mean+s.e.m.). viral gene products within the CNS, but also with glial activation. By morphological criteria, these activated cells within the brain consisted mainly of microglia cells (S Czub, unpublished observation). Previously, it had been demonstrated that activation of microglia ± due to focal CNS injury ± enhanced the susceptibility of these cells for retroviral infection (Lynch et al, 1995) . Likewise, Selegiline is known of being capable to increase reactive gliosis (Biagini et al, 1993 (Biagini et al, , 1994 Ju et al, 1994) . It is thus possible that Selegiline by increasing reactive gliosis enhanced the susceptibility for retroviral infection within the CNS. Whether Selegiline has a direct effect on microglia or rather on other glia cells, like astrocytes, and by this an indirect in¯uence on microglia cells remains to be determined. It must also be proven whether Selegiline might have a more direct effect on viral spread and/ or on viral transcription.
Additionally, it is possible that Selegiline triggered endogenous mechanism(s) that could directly be involved in the pathogenesis of retroviral neurodegeneration and subsequently led to enhanced neurological disease. Those mechanisms might include production of neurotransmitters, cytotoxins, interference with neural growth factors and/or loss of scavenger functions within the CNS (Masliah et al, 1996) .
The effects of Selegiline observed in this study could be due to either (1) an increase of dopamine (Gerlach et al, 1996) , (2) to the metabolites of Selegiline, especially amphetamine and metamphetamine (Gerlach et al, 1996) , or (3) to an induction of gene expression (Tatton and Chalmers-Redman, 1996) . Amphetamine and metamphetamine, and/ or inhibition of MAO-B and a subsequent increase of dopamine is unlikely to have played a role for enhancement of neurological disease, since neurological disease was not accelerated when MAO-B was inhibited by Selegiline given before the time spongiform neurodegeneration occurred. However, it is possible that at this early time a critical stage of postnatal CNS development prevented rats from becoming susceptible to enhanced retroviral neurodegeneration. This hypothesis is supported by ®ndings on prenatal, i.e. in utero infection of mice with neurovirulent MuLV, after which brains of these mice had high levels of viral load already at birth, however, neurological disease did not start before 15 days postnatally and was thus not accelerated in comparison to postnatal infection (Lynch and Portis, 1993) .
According to recent studies, transcriptional activation rather than inhibition of MAO-B is supposed to play a key role for neuroprotective effects of Selegiline (Semkova et al, 1996; Tatton and Chalmers-Redman, 1996; ThyagaRajan et al, 1998) . In that same sense, Selegiline induced activation of glia cells ± as demonstrated by enhanced expression of MHC II in our study ± might have been bene®cial for the CNS, under normal circumstances. However, due to their activated metabolism, brain cells were more susceptible to retroviral infection and expressed retroviral gene products to a higher degree. As a result, neurological disease was accelerated. Our ®ndings may be relevant for other viral infections of the brain, like HIV, in which activation of the glia cells, e.g. by dopamimetic substances, could rather be harmful than helpful (Bell et al, 1996; Davies et al, 1997; Martinez et al, 1995) .
Material and methods

Animal model
Neonatal Fisher (F344) rats were inoculated intraperitoneally (ip) with MuLV-NT40 (10 4 focus forming units) which leads to persistent infection of several peripheral organs and the brain . There is no immune response towards the neonatal viral infection and no in¯ammation within degenerated brain tissue .
Selegiline was given ip at day 13, i.e. before spongiform neurodegeneration occurred, or at day 17 post infection, i.e. after neurovacuolation had started. For single dose effects in adult rats, 0.25 mg Selegiline per kg bodyweight has been reported to inhibit MAO-B completely (Knoll, 1993) . For each scheme of treatment, 3 ± 17 experiments were set up independently. Animals were killed by CO 2 inhalation. All experiments were performed on the permission of the State of Bavaria, Germany, and in accordance with Federal and EU guidelines.
Neurological testing Re¯ex functions were tested by lifting each animal by the tail and placing it on the edge of the cage (grabbing re¯ex) and by short falls (placing re¯ex). Later signs of neurological disease are ataxia and paralysis. Animals were scored positive for neurological disease when they repeatedly exhibited neurological signs. Selegiline injected into noninfected rats did not induce neurological signs (data not shown).
Measurement of MAO-B activity (Tipton and Singer, 1993) Striata of rats were disrupted in 0.25 M Saccharose in PBS (pH 7.4, 0.1 M) on ice using a glass homogenizer and a soni®cator. Homogenates (225 ml containing 400 mg protein) were incubated in a shaking waterbath at 378C for 5 min. Twenty®ve ml of b-[ethyl-1-14 C]-phenylethylamine hydrochloride (PEA, 100 mM, speci®c activity 1.55 Gbq/ mmol; DuPont NEN) in 0.1 M PBS were added to 225 ml homogenate and incubated at 378C for 7 min. After adding 250 ml of 1 M HCl, the acidi®ed solution was extracted with 2 ml of ethyl acetate by vigorous shaking for 15 min. After centrifugation at 10006g for 5 min, two phases were separated and 1 ml of the organic phase containing the deaminated metabolites was counted with 4 ml of biosolve cocktail (Rotiszint, Roth) in a liquid scintillation counter (Beckmann Instruments). MAO activity is given as nmol of products formed per mg protein per min. Recovery of labeled products was 98% of total radioactivity used. Values were corrected for blank activity and counting was quench corrected.
Immunohistochemistry and in situ hybridization Tissues were ®xed in 3% formalin-PBS and embedded in paraf®n. Immunohistochemistry and in situ hybridization was performed as described before . Brain cells positive for antiviral staining were counted in high power view (magni®cation 6200) using an ocular grid (ten full ®elds per individual). Major histocompatibility complex class II molecules (MHC II) were recognized by monoclonal antibody OX6 (McMaster and Williams, 1979) .
Quanti®cation of viral transcripts mRNA was isolated from total brains employing Oligo(dT) 25 Dynabeads following the recommendations of the manufacturer (Dynal). After Northern blotting, blots were probed with a viral envelope speci®c-probe as well as with a probe for a housekeeping gene, rat glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Virus speci®c hybridization signals were adjusted to comparable levels by dividing the individual signal strengths of the viral signals by the respective signal strengths of the GAPDH signals.
32 P-hybridization signals were analyzed and background corrected using a Phosphor imaging system and Image Quant software from Molecular Dynamics.
Statistical analyses
Incubation periods, MAO-B inhibition, and numbers of brain cells expressing viral gene products and MHC II, respectively, are given as mean+ standard error of the mean (s.e.m.). On these data, statistics were performed using Student's t-test. Kaplan-Meyer curves (Figure 1) were analyzed using rank ANOVA testing (Kruskal-Wallis-H test).
